Does information by pharmacists convince the public to get vaccinated for pneumococcal disease and herpes zoster?

Bayraktar-Ekincioglu, Aygin; Kara, Emre; Bahap, Melda; Cankurtaran, Mustafa; Demirkan, Kutay; Ünal, Serhat

doi:10.1007/s11845-021-02778-x

Cited by 3 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 1 describes the characteristics of the included four RCTs studies (Heaton et al, 2022 ; Klassing et al, 2018 ; Ozdemir et al, 2023 ; Stolpe & Choudhry, 2019 ) and 15 non-RCTs studies (Abu-rish et al, 2021 ; Are et al, 2022 ; Bacci et al, 2019 ; Bayraktar-Ekincioglu et al, 2022 ; Cebollero et al, 2020 ; Deslandes et al, 2020 ; Fathima et al, 2021 ; Gatwood et al, 2022 ; Goldsworthy et al, 2022 ; Goode et al, 2023 ; Howe et al, 2022 ; Page et al, 2020 ; Rihtarchik et al, 2018 ; Scherrer et al, 2020 ; Villaverde Piñeiro et al, 2022 ). Two RCTs (Klassing et al, 2018 ; Stolpe & Choudhry, 2019 ) which were both conducted in the USA, evaluated the impact of technology-based systems that facilitated the advocacy strategies of pharmacists in identifying patients for vaccine recommendations.…”

Section: Resultsmentioning

confidence: 99%

“…Comparison: Without pharmacists immunisation authority Influenza Number of vaccine recipients 1 year ≥18 344,126/27,681 Critical risk Bacci et al, 2019 United States Non-RCT a Community c Advocator i / Immuniser Monitoring system j A technology system, integrated in the pharmacies workflow that enable proactive checking of the immunisation information system and forecasting of and recommendation to patients about their vaccine needs. Comparison: Usual care Influenza Pneumococcal Pertussis Herpes zoster Number of vaccine doses administered 1 year ≥18 84,488/84,488 Moderate risk Bayraktar-Ekincioglu et al, 2022 Turkey Non-RCT a Community e Advocator f Monitoring system l Pharmacists provide education to participants regarding vaccines. Comparison: Usual care Pneumococcal Herpes zoster Number of vaccine recipients 6 months ≥50 122/249 Serious risk Cebollero et al, 2020 United States Non-RCT a Community d Advocator f,g,h,i,m /Immuniser Monitoring system l Pharmacists ensure stock availability, promoting,screening, vaccine administration,education, creation of vaccine workflow for HCP with daily and weekly support visits.…”

Section: Resultsmentioning

confidence: 99%

“…One study (Howe et al, 2022 ) assessed the impact of providing funding to community pharmacies to encourage vaccination uptake. Seven studies (Abu-rish et al, 2021 ; Bayraktar-Ekincioglu et al, 2022 ; Cebollero et al, 2020 ; Fathima et al, 2021 ; Goldsworthy et al, 2022 ; Goode et al, 2023 ; Scherrer et al, 2020 ) evaluated the implementation of a quality improvement programme by pharmacists to improve immunisation rates. In these studies, a comparison was made of 20 different comparator interventions against pharmacist-led interventions.…”

Section: Resultsmentioning

confidence: 99%

“…Pharmacist-led approaches included pharmacists reviewing vaccination history and recommending vaccines to potential recipients or to the doctors in-charge (recruitment) (8 studies, 40%) (Abu-rish et al, 2021 ; Bayraktar-Ekincioglu et al, 2022 ; Cebollero et al, 2020 ; Fathima et al, 2021 ; Goldsworthy et al, 2022 ; Goode et al, 2023 ; Rihtarchik et al, 2018 ; Scherrer et al, 2020 ), patient education (7 studies, 35%) (Abu-rish et al, 2021 ; Bayraktar-Ekincioglu et al, 2022 ; Cebollero et al, 2020 ; Fathima et al, 2021 ; Goldsworthy et al, 2022 ; Goode et al, 2023 ; Scherrer et al, 2020 ), training (2 studies, 10%) (Cebollero et al, 2020 ; Goode et al, 2023 ), organising campaigns (2 studies, 10%) (Cebollero et al, 2020 ; Goode et al, 2023 ), and stocking up on vaccines (1 study, 5%) (Cebollero et al, 2020 ). Most of these studies were from the USA (7 studies, 63.6%) (Bacci et al, 2019 ; Cebollero et al, 2020 ; Gatwood et al, 2022 ; Goldsworthy et al, 2022 ; Goode et al, 2023 ; Rihtarchik et al, 2018 ; Scherrer et al, 2020 ) and one study each from Turkey (9.1%) (Bayraktar-Ekincioglu et al, 2022 ), New Zealand (9.1%) (Howe et al, 2022 ), Jordan (9.1%) (Abu-rish et al, 2021 ) and Australia (9.1%) (Fathima et al, 2021 ). These studies were primarily conducted in community settings: four community pharmacies (36.3%) (Bacci et al, 2019 ; Fathima et al, 2021 ; Gatwood et al, 2022 ; Howe et al, 2022 ), three primary healthcare clinics (27.2%) (Cebollero et al, 2020 ; Goldsworthy et al, 2022 ; Goode et al, 2023 ), one community centre (9.1%) (Goldsworthy et al, 2022 ), and three hospitals (27.2%) (Abu-rish et al, 2021 ; Rihtarchik et al, 2018 ; Scherrer et al, 2020 ).…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Impact of pharmacist interventions on immunisation uptake: a systematic review and meta-analysis

Rahim,

Dom,

Hamzah

et al. 2023

Journal of Pharmaceutical Policy and Practice

View full text Add to dashboard Cite

Background Under-utilisation of immunisation services remains a public health challenge. Pharmacists act as facilitators and increasingly as immunisers, yet relatively little robust evidence exists of the impact elicited on patient health outcome and vaccination uptake. Objective To evaluate the influence of pharmacist interventions on public vaccination rate. Methods SCOPUS, PubMed, and Web of Science were searched from inception to April 2023 to retrieve non- and randomised controlled clinical trials (RCTs). Studies were excluded if no comparator group to pharmacist involvement was reported. Data extraction, risk of bias assessments, and meta-analyses using random-effect models, were performed. Results Four RCTs and 15 non-RCTs, encompassing influenza, pneumococcal, herpes zoster, and tetanus-diphtheria and pertussis vaccine types, and administered in diverse settings including community pharmacies, were included. Pooled effect sizes revealed that, as compared to usual care, pharmacists, regardless of their intervention, improved the overall immunisation uptake by up to 51% [RR 1.51 (1.28, 1.77)] while immunisation frequency doubled when pharmacists acted specifically as advocators [RR 2.09 (1.42, 3.07)]. Conclusion While the evidence for pharmacist immunisers was mixed, their contribution to immunisation programmes boosted public vaccination rate. Pharmacists demonstrated leadership and acquired indispensable advocator roles in the community and hospital settings. Future research could explore the depth of engagement and hence the extent of influence on immunisation uptake.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Impact of pharmacist interventions on immunisation uptake: a systematic review and meta-analysis

Rahim,

Dom,

Hamzah

et al. 2023

Journal of Pharmaceutical Policy and Practice

View full text Add to dashboard Cite

show abstract

“…Out of 543 patients aged ≥ 65 years admitted to outpatient clinics, 6.6% had previously heard of HZ vaccination [ 98 ]. A prospective study carried out at five centers in Turkey ( N = 155) reported that 12.7% of individuals had knowledge of HZ vaccination [ 97 ], while another survey of 100 participants aged 19–63 years in Anatalya noted that only 1% had knowledge of HZ vaccination [ 96 ]. However, a survey of 263 Turkish family physicians in 2014 revealed that 59.7% had knowledge of HZ vaccination and 65.7% would recommend the vaccine [ 103 ].…”

Section: Resultsmentioning

confidence: 99%

Herpes Zoster Burden of Disease and Clinical Management in Turkey: A Comprehensive Literature Review

Badur,

Senol,

Azap

et al. 2023

Infect Dis Ther

View full text Add to dashboard Cite

Introduction Herpes zoster (HZ), or shingles, is caused by the reactivation of varicella zoster virus (VZV) and typically presents as an acute, painful dermatomal rash, but can lead to long-term, distressing complications such as postherpetic neuralgia (PHN). Increasing trends in HZ cases are evident globally among the aging population; however, reviews investigating the epidemiology and clinical management of HZ in Turkey are lacking. Therefore, a literature review of local studies in Turkey was conducted to identify the data available and identify gaps in the literature. Methods Literature searches were carried out in PubMed and local journals to retrieve published articles that reported surveillance data, seroepidemiology, patient outcomes, or clinical management related to HZ or VZV in Turkey until April 30, 2022. Studies included primary data reports, case studies, secondary data reviews, and epidemiological studies in healthy or at-risk populations; HZ was the primary focus of the review. Results No studies reported VZV or HZ epidemiological data at a national level. One large retrospective study in Istanbul reported that HZ incidence rates significantly increased in adults 18–44 years of age between 2011 and 2019. Four single-center studies reported the proportion of dermatological patients with HZ at 0.43–1.56%. PHN was the most common reported complication, occurring in 8–58.9% of patients with HZ. However, out of 39 identified case reports, HZ ophthalmicus was the most frequently reported complication. Two studies highlighted poor disease awareness and risk perception of HZ among Turkish citizens. Conclusion Overall, there were limited comprehensive epidemiological data on HZ in Turkey. However, the abundance of case studies on HZ complications indicates a strong disease presence and diverse clinical management in Turkey. Further research will be important to understand the impact of HZ, increase disease awareness, and support the introduction of new preventative strategies. Supplementary Information The online version contains supplementary material available at 10.1007/s40121-023-00849-3.

show abstract

The acceptability of and willingness to pay for a herpes zoster vaccine: A systematic review

Thi Bich Tran,

Quang Vo,

Thi Khanh Tran

et al. 2023

BIO Web Conf.

View full text Add to dashboard Cite

Patients, predominantly the elderly, with Herpes Zoster (HZ) not only suffer symptoms of the disease but also bear considerable expenses. This study systematically reviewed the acceptability of and willingness to pay for the HZ vaccine. This review was registered in PROSPERO 2023 (CRD42023403062). We used “acceptance”, “willing to pay”, and “HZ vaccine” (and variations thereof) as keywords in a systematic search for original English research articles published up to April 7, 2023. The search was conducted over Scopus, PubMed, ScienceDirect, Cochrane, and Google Scholar in accordance with PRISMA 2020 guidelines. The inclusion criteria were as follows: studies (1) that mentioned HZ vaccination, (2) related to acceptability or willingness to pay, and (3) with full texts available and peer-reviewed prior to final publication. Grey literature, letters to editors, commentaries, case reports or series, systematic reviews, meta-analyses, articles of poor quality, and articles with ambiguously defined and measured outcome variables were excluded. The Joanna Briggs Institute (JBI) critical appraisal checklist was used to evaluate the methodological quality of the studies. Finally, the search yielded 24 studies, of which 9 were conducted in Asia, 8 in Europe, and 7 in America. General adults or patients aged 50 or older were often the target populations, for whom treatments were accompanied by healthcare providers’ recommendations. The willingness to pay and willingness to accept the vaccine ranged from $8 to $150 and 16.6% to 85.8%, respectively. Compared to the US, Asia and Europe had higher acceptance rates for HZ immunization. The most frequent excuses given for not being vaccinated are side effects, cost, lack of recommendations, anti-vaccination views, ignorance about the HZ vaccine, and the belief that one is not at risk for the disease. National campaigns should be developed to increase public awareness of HZ, and more international research should be conducted to understand the WTA and WTP for HZ immunizations.

show abstract

Does information by pharmacists convince the public to get vaccinated for pneumococcal disease and herpes zoster?

Cited by 3 publications

References 23 publications

Impact of pharmacist interventions on immunisation uptake: a systematic review and meta-analysis

Impact of pharmacist interventions on immunisation uptake: a systematic review and meta-analysis

Herpes Zoster Burden of Disease and Clinical Management in Turkey: A Comprehensive Literature Review

The acceptability of and willingness to pay for a herpes zoster vaccine: A systematic review

Contact Info

Product

Resources

About